ANI Pharmaceuticals, Inc.

Equities

ANIP

US00182C1036

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
69.13 USD -0.80% Intraday chart for ANI Pharmaceuticals, Inc. -0.27% +25.37%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP CI
Capital One Initiates ANI Pharmaceuticals at Overweight Rating MT
Ani Pharmaceuticals Insider Sold Shares Worth $671,700, According to a Recent SEC Filing MT
Ani Pharmaceuticals Insider Sold Shares Worth $2,630,864, According to a Recent SEC Filing MT
Ani Pharmaceuticals Insider Sold Shares Worth $456,400, According to a Recent SEC Filing MT
Ani Pharmaceuticals Insider Sold Shares Worth $330,000, According to a Recent SEC Filing MT
Guggenheim Adjusts ANI Pharmaceuticals' Price Target to $77 From $70, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on ANI Pharmaceuticals to $83 From $73, Maintains Buy Rating MT
Truist Securities Raises Price Target on ANI Pharmaceuticals to $80 From $72, Maintains Buy Rating MT
Sector Update: Health Care Stocks Decline Late Afternoon MT
Sector Update: Health Care Stocks Retreat Thursday Afternoon MT
ANI Pharmaceuticals Shares Rise After Q4 Adjusted Earnings, Net Revenue Beat Forecasts MT
Transcript : ANI Pharmaceuticals, Inc., H2 2023 Earnings Call, Feb 29, 2024
ANI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024 CI
(ANIP) ANI PHARMACEUTICALS Sees Fiscal Year 2024 Revenue Range $520M - $542M MT
(ANIP) ANI PHARMACEUTICALS Expects Fiscal Year 2024 EPS Range $4.26 - $4.67 MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Posts Q4 Revenue $131.7M, vs. Street Est of $124.9M MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Reports Q4 EPS $1.00, vs. Street Est of $0.86 MT
ANI Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Truist Securities Adjusts Price Target on ANI Pharmaceuticals to $72 From $70, Maintains Buy Rating MT
Ani Pharmaceuticals Insider Sold Shares Worth $1,416,466, According to a Recent SEC Filing MT
ANI Pharmaceuticals Launches Pentoxifylline Extended-Release Tablets MT
ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP CI
Ani Pharmaceuticals Insider Sold Shares Worth $1,370,305, According to a Recent SEC Filing MT
Chart ANI Pharmaceuticals, Inc.
More charts
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
69.13 USD
Average target price
79.8 USD
Spread / Average Target
+15.43%
Consensus
  1. Stock
  2. Equities
  3. Stock ANI Pharmaceuticals, Inc. - Nasdaq
  4. News ANI Pharmaceuticals, Inc.
  5. ANI Pharmaceuticals : Q4 Adjusted Earnings Drop, Revenue Rises; Acquires Novitium Pharma for $163.5 Million